Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs

Figure 2

Protectiveness of vaccine samples in guinea pigs estimated by the amount allocated to Brucella from tissues and organs (a) and index of infection (b). Animals were vaccinated at regime of prime-boost at interval of 21 days with mono-, bi-, or tetravalent vaccine formulations or a single delivery of commercial vaccine B. melitensis Rev.1. Guinea pigs in the negative control group were delivered with PBS. The challenge of animals was performed with virulent strain of B. melitensis 16M at a dose of 1.3 log₁₀ CFU/animal using an s.c. route. Bacteriological evaluation was assessed by counting Brucella colonies in tissues, where data is expressed as log₁₀ CFU/g and the index of infection in animals (the arithmetic was given for each group; number of tissues from where Brucella was isolated for each animal). Statistical analysis for (a) was performed using a one-way ANOVA followed by Tukey’s multiple comparison test, and for (b) two-way ANOVA followed by Sidak’s multiple comparison test. From to ; from to ; from to ; .

(a)

(b)